(KROS) Keros Therapeutics - Ratings and Ratios

Keros Therapeutics, Inc. (NASDAQ:KROS) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. This signaling pathway plays a crucial role in various cellular processes, making it a significant target for therapeutic intervention. The companys lead product candidate, KER-050, is under development for treating cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. KER-050 aims to address these conditions by targeting the underlying pathological mechanisms associated with TGF-β signaling.

Additionally, Keros Therapeutics is advancing KER-012, which is currently in Phase II clinical trials for the treatment of pulmonary arterial hypertension (PAH) and other cardiovascular disorders. KER-065 is another promising candidate in the companys pipeline, currently in Phase I clinical trials for the treatment of obesity and neuromuscular diseases. These developments highlight the companys commitment to addressing a range of conditions through its innovative approach to TGF-β signaling modulation.

Keros Therapeutics has also established a strategic collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd., focusing on the development, manufacturing, and commercialization of KER-050 and other products containing this candidate. This partnership underscores the companys efforts to expand its reach and accelerate the delivery of its therapies to patients. Founded in 2015 and headquartered in Lexington, Massachusetts, Keros Therapeutics continues to build its reputation as a dedicated player in the biopharmaceutical industry.

Ticker Symbol: KROS Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Average Volume 20d: 1,052,166 Last Price: 11.01 SMA 20: 10.85 SMA 50: 13.08 SMA 200: 42.98 ATR: 0.70

Market Cap: 446.39M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.84 P/S: 685.70 RoE: -34.08

3-Month Forecast: Based on the provided data, KROS is expected to face headwinds due to its position below the SMA 50 and SMA 200, indicating a bearish trend. However, the stock may find support near the SMA 20 (~10.85). The ATR of 0.70 suggests moderate volatility, with potential price swings. On the fundamental side, the high P/S ratio (685.70) indicates a speculative valuation, while the negative RoE (-34.08) reflects ongoing losses. The companys pipeline progress, particularly KER-050s development, will be a key driver. If positive trial data emerges, it could act as a catalyst, potentially pushing the stock towards resistance at the SMA 50 (~13.08). Conversely, any setbacks could lead to a retest of recent lows.